Search Results
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
EudraCT No. 2020-003016-27) is a randomized Phase 3 trial in R/R LBCL evaluating epcoritamab, a CD3×CD20 bispecific antibody, monotherapy. The study showed a statistically significant improvement in PFS versus investigator's choice of chemoimmunotherapy
More news about: AbbVie
Jun 08, 2026, 07:00 ET Dualitas Therapeutics Appoints Karim Dabbagh as Chief Executive Officer to Advance Novel Bispecific Antibody Pipeline Toward the Clinic
achieved with monospecific agents. Dualitas is applying its bispecific proximity engager across multiple validated immune pathways, starting with the CD28 pathway for its DTX-102 program. In vitro and in vivo preclinical studies of DTX-102 demonstrated significantly greater potency and more durable immune
More news about: Dualitas Therapeutics
Jun 08, 2026, 05:01 ET Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress
KT209KT209 is a novel CD19 x CD20 x CD3 trispecific antibody engineered using Kali's proprietary multi-specific antibody platform. It is designed to maximize therapeutic efficacy by simultaneously binding to two distinct B-cell antigens (CD19 and CD20) and co-engaging CD3 on T cells. This dual-targeting
More news about: Kali Therapeutics
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102
More news about: Antengene Corporation Limited
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Updated March 1, 2024. Accessed May 14, 2026.Fryar CD, Afful J, Saif NT. Prevalence of overweight, obesity, and severe obesity among adults age 20 and over: United States, 1960–1962 through August 2021-August
More news about: Amgen
Jun 05, 2026, 08:00 ET Hitachi and Intel announce strategic collaboration to accelerate AI transformation across key industries
of foundry tools, Hitachi gathers high-precision data generated from its market-leading metrology systems, dimension scanning electron microscopes (CD-SEMs), as well as etching systems, on the integrated platform "ExTOPE." Leveraging physical AI, Hitachi uses that data to enable predictive diagnostics
More news about: Hitachi Americas
Jun 05, 2026, 08:00 ET Hitachi and Intel announce strategic collaboration to accelerate AI transformation across key industries
of foundry tools, Hitachi gathers high-precision data generated from its market-leading metrology systems, dimension scanning electron microscopes (CD-SEMs), as well as etching systems, on the integrated platform "ExTOPE." Leveraging physical AI, Hitachi uses that data to enable predictive diagnostics
More news about: Hitachi Americas
Jun 04, 2026, 12:00 ET Kinefinity Vista Full-Frame 6K Digital Cinema Camera Announced; More Info at B&H Photo
palette.One major update from previous generations of Kinefinity cameras is the Vista camera's articulated onboard monitor. This 4" OLED touchscreen with 700 cd/m² brightness can flip out and rotate up to 360° for optimal viewing. It offers tactile Record, Playback, and Menu buttons, five-way navigation, and
More news about: B&H Photo
Jun 04, 2026, 02:30 ET AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren's Disease at EULAR 2026
2026 show that CD45RC is highly expressed within lymphocytic infiltrates and selectively localizes to disease-affected regions of salivary glands from patients with SjD. CD45RC expression levels strongly correlate with the degree of lymphocytic infiltration. These findings support CD45RC as both a promising
More news about: AbolerIS Pharma
Jun 03, 2026, 17:00 ET Blood Cancer Treatment Allows Hard-to-Match Kidney Failure Patients to Receive a Compatible Kidney Transplant
sensitized patients.Repurposing CAR T Therapy for Transplant AccessThe experimental approach combines two engineered T cell therapies: CD19‑targeted CAR T cells, which eliminate memory B cells, and BCMA‑targeted CAR T cells, which deplete antibody‑producing plasma cells. By removing both
More news about: NYU Langone Health
Jun 03, 2026, 16:05 ET ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
be available for 30 days following the call.About ZYNLONTA®ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The
More news about: ADC Therapeutics SA
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
IMDYLLTRA ist die erste zielgerichtete Immuntherapie ihrer Klasse, die von Amgen-Forschern entwickelt wurde, um sowohl an DLL3 auf Tumorzellen als auch an CD3 auf T-Zellen zu binden und dadurch T-Zellen zu aktivieren, um DLL3-exprimierende SCLC-Zellen abzutöten. Dies führt zur Bildung einer zytolytischen Synapse
More news about: Amgen
Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU
immunothérapie ciblée, la première de sa catégorie, conçue par les chercheurs d'Amgen pour se lier à la fois au DLL3 sur les cellules tumorales et au CD3 sur les cellules T, activant ainsi les cellules T pour qu'elles tuent les cellules CPPC exprimant DLL3. Il en résulte la formation d'une synapse cytolytique
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
prvá cielená imunoterapia svojho druhu, ktorú vyvinuli vedci spoločnosti Amgen tak, aby sa viazala na molekulu DLL3 na nádorových bunkách a zároveň na CD3 na T-lymfocytoch, čím aktivuje T-lymfocyty na ničenie SCLC buniek exprimujúcich DLL3. Tým sa vytvára cytolytická synapsia, ktorá vedie k lýze nádorovej
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
je první cílená imunoterapie svého druhu, vyvinutá výzkumníky společnosti Amgen tak, aby se vázala jak na protein DLL3 na nádorových buňkách, tak na CD3 na Т-buňkách, čímž aktivuje Т-buňky k ničení buněk SCLC exprimujících DLL3. Výsledkem je vytvoření cytolytické synapse s lýzou rakovinné buňky. 5,6 DLL3
More news about: Amgen
Jun 03, 2026, 11:15 ET i2k2 Networks Honoured as AWS Rising Star Consulting Partner of the Year -- India 2026
enterprise. At i2k2, we have been at the forefront of this shift, helping our customers harness the power of AI and machine learning on AWS, build robust CI/CD pipelines, and adopt modern DevOps practices that dramatically accelerate their time to market. From deploying generative AI workloads on Amazon Bedrock
More news about: i2k2 Networks Pvt. Ltd.
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
ukierunkowana immunoterapia opracowana przez naukowców firmy Amgen, zaprojektowana tak, aby wiązać się zarówno z DLL3 na komórkach nowotworowych, jak i z CD3 na limfocytach T, co prowadzi do ich aktywacji i niszczenia komórek drobnokomórkowego raka płuca (SCLC) wykazujących ekspresję DLL3. W wyniku tego dochodzi
More news about: Amgen
Jun 03, 2026, 10:01 ET T-cell Malignancies Market to Accelerate Substantially at a CAGR of 5.2% During the Forecast Period (2026-2036) | DelveInsight
biologically driven treatment strategies.The current PTCL therapeutic landscape includes approved agents such as brentuximab vedotin by Takeda for CD30-positive disease, romidepsin from Bristol Myers Squibb, belinostat by Acrotech BioPharma, mogamulizumab from Kyowa
More news about: DelveInsight Business Research, LLP
Jun 03, 2026, 09:43 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ
является первой в своем классе таргетной иммунотерапией, разработанной исследователями Amgen для связывания как с DLL3 на опухолевых клетках, так и с CD3 на Т-клетках, тем самым активируя Т-клетки для уничтожения DLL3-экспрессирующих клеток МРЛ. Это приводит к образованию цитолитического синапса с лизисом
More news about: Amgen
Jun 03, 2026, 09:27 ET LA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO
IMDYLLTRA es una inmunoterapia dirigida pionera, desarrollada por investigadores de Amgen para unirse tanto a DLL3 en las células tumorales como a CD3 en las células T, activando así las células T para eliminar las células de cáncer de pulmón de células pequeñas (CPCP) que expresan DLL3. Esto da como
More news about: Amgen
Jun 03, 2026, 09:07 ET June 2026 CD Rate Trends: CD APY Increases are Accelerating, According to CD Valet
existing CD early – and reinvesting at a higher rate – could increase their net return.About CD Valet CD Valet is a CD marketplace that features verified CD rates from federally insured banks and credit unions. With tens of thousands of CD offers tracked across the country, CD Valet
More news about: CD Valet
Jun 03, 2026, 09:00 ET Kosli Partners with Adaptavist to Automate Governance for AI Assisted Software Delivery
machine speed, legacy governance processes for managing slow inspection and release cycles can't keep up.A decade of advances in DevOps and CI/CD has exposed the limits of manual governance processes, and AI driven development is about to completely overwhelm them. When AI driven software delivery
More news about: Kosli AS
Jun 03, 2026, 09:00 ET AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
involvement over time, including the emergence of new organ manifestations and biological signals that may precede disease flares.1CD19+ B cells were the first biomarker to rise ahead of a flare, followed by increases in total IgG and IgG subsets within the 30-day window preceding a
More news about: Amgen
Jun 03, 2026, 08:30 ET CLPS Incorporation Restructures R&D Architecture, Introduces AI Rainstorm Factory Development Model
R&D Workshops: Based on the generated FSDs and TSDs, developers leverage AI to generate executable code, produce high-quality code that passes CI/CD pipelines to merge into the main branch, create unit test cases, and execute front-end/back-end integration.Automated Testing
More news about: CLPS
Jun 03, 2026, 08:00 ET Invicti introduces all-in-one application security platform
findingsDAST to SAST Correlation: Maps runtime issues directly to code and originating developer for faster fixesWith built-in integrations for CI/CD pipelines, issue tracking, notifications, and developer security training platforms, AppSec Core minimizes setup effort and reduces ongoing maintenance.Keep
More news about: Invicti Security